MEA consists of three major countries namely United Arab Emirates (UAE), Saudi Arabia and South Africa. The market is driven by the factors such as increasing government initiatives, growing number of kidney diseases, increasing technologies and product launches and approvals in the region.
Lockdowns imposed during the COVID-19 pandemic caused people to delay health checkups, which resulted in reduction in the number of tests performed. Also, the market suffered losses due to limited production, supply chain facilities, and business shutdown. The pandemic affected the business operations of the various key urinalysis market players. According to National Kidney Foundation, patients hospitalized for the treatment of COVID-19 are at significant risk of acute kidney injury that can cause severe illness and death. The recovered patients need to be under continuous medical observation, while the patients having blood or protein in their urine should also be monitored as they are also at a high risk of developing chronic kidney diseases. The pandemic has also impacted the regulatory environment and practices, as governments and healthcare providers face considerable challenges to meet the market demand due to increasing cases. However, the continuation of procedures can be seen as countries gradually ease their restrictions and regulatory authorities speed up approval of diagnostic products helping the market grow.
Market Overview and Dynamics
The urinalysis market in MEA is expected to grow from US$ 186.27 million in 2021 to US$ 239.74 million by 2028; it is estimated to grow at a CAGR of 3.7% from 2021 to 2028. The demand for components required for urinalysis is rising due to the common occurrence of diabetes across the region, as the primary screening for diabetes involves urinalysis. Moreover, according to a study published by the National Kidney Foundation in 2020, ~35.0% of the diabetic population above age 20 would develop chronic kidney diseases over the period. An ongoing surge in the prevalence of prostate and bladder cancer raises a strong therapeutic imperative for the implementation of highly effective diagnostics. Thus, the escalating prevalence of UTIs, diabetes, and kidney diseases boosts MEA urinalysis market growth.
Key Market Segments
MEA urinalysis market is segmented into product, test type, application, end user, and country. Based on product, the MEA urinalysis market is segmented into consumables and instruments. The consumables segment is expected to hold a larger market share in 2021. The MEA urinalysis market, based on test type, is segmented into pregnancy and fertility tests, biochemical urinalysis, and sediment urinalysis. The biochemical urinalysis segment would hold the largest share of the market in 2021. Based on application, the MEA urinalysis market is segmented into disease screening and pregnancy, and fertility. The disease screening segment would account for a larger market share in 2021. The MEA urinalysis market, by end user, is segmented into hospitals and clinics, diagnostic laboratories, home care settings, and research laboratories and institutes. The hospitals and clinics segment would hold the largest share of the market in 2021. Based on country, the MEA urinalysis market is segmented into Saudi Arabia, South Africa, UAE, and rest of MEA. South Africa held the largest market share in 2021.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the urinalysis market in MEA are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Abbott; ACON Laboratories, Inc.; ARKRAY, Inc.; Beckman Coulter, Inc.; Bio-Rad Laboratories Inc.; Cardinal Health Inc; F. Hoffmann-La Roche Ltd.; Siemens Healthineers AG; and Sysmex Corporation.
Reasons to buy report
- To understand the MEA urinalysis market landscape and identify market segments that are most likely to guarantee a strong return.
- Stay ahead of the race by comprehending the ever-changing competitive landscape for MEA urinalysis market.
- Efficiently plan M&A and partnership deals in MEA urinalysis market by identifying market segments with the most promising probable sales.
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form MEA urinalysis market.
- Obtain market revenue forecast for market by various segments from 2021-2028 in MEA region.
MEA Urinalysis Market Segmentation
MEA Urinalysis Market - By Product
- Consumables
- Instruments
MEA Urinalysis Market - By Test Type
- Pregnancy and Fertility Tests
- Biochemical Urinalysis
- Sediment Urinalysis
MEA Urinalysis Market - By Application
- Disease Screening
- Pregnancy and Fertility
MEA Urinalysis Market - By End User
- Hospitals and Clinics
- Diagnostic Laboratories
- Home Care Settings
- Research Laboratories and Institutes
MEA Urinalysis Market - By Country
- Saudi Arabia
- South Africa
- UAE
- Rest of the MEA
MEA Urinalysis Market - Company Profiles
- Abbott
- ACON Laboratories, Inc.
- ARKRAY, Inc.
- Beckman Coulter, Inc.
- Bio-Rad Laboratories Inc.
- Cardinal Health Inc
- F. Hoffmann-La Roche Ltd.
- Quidel Corporation
- Siemens Healthineers AG
- Sysmex Corporation
Middle East and Africa Urinalysis Market Strategic Insights
Middle East and Africa UrinalysisMarket Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 186.27 Million |
| Market Size by 2028 | US$ 239.74 Million |
| CAGR (2021 - 2028) | 3.7% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product
|
|
Regions and Countries Covered
|
|
| Middle East and Africa | South Africa, Saudi Arabia, UAE, Rest of Middle East and Africa |
| Market leaders and key company profiles |
|
Middle East and Africa Urinalysis Market Country and Regional Insights
